Skip to main content
. 2016 Aug 26;7(41):66809–66821. doi: 10.18632/oncotarget.11631

Figure 5. Tumor sensitivity to JQ1 was dependent on PTEN status in vivo.

Figure 5

(A) The Hec-1a xenografts with PTEN loss presented resistance to JQ1 after 4 weeks of treatment (p = 0.039). (B) PTEN loss in Hec-1a xenografts significantly increased tumor weights (p = 0.027) (C and D) IHC results showed that the protein expression of Ki-67 and phospho-AKT were increased in Hec-1a xenografts with PTEN-knockdown (p = 0.05 and 0.003, respectively). (E) AN3CA xenografts with PTEN knock-in became much more sensitive to JQ1 than their parental ones after 4 weeks of treatment (p = 0.014). (F) The tumor weights were also decreased in AN3CA xenografts with PTEN loss (p = 0.036). (G and H) The expression of Ki 67 and p-AKT were decreased in the tumor tissues with abundant PTEN in AN3CA xenografts (p = 0.041 and 0.018, respectively).